Friday, December 29, 2017

Study shows cannabidiol has potential to treat schizophrenia


A study published Dec. 5 by the American Journal of Psychiatry shows that cannabidiol (CBD), a substance found in marijuana, could have beneficial effects in patients with schizophrenia.

A group of trial patients took 1000mg of CBD per day along with their existing antipsychotic medication. After six weeks of treatment, compared with a placebo group, the CBD group had lower levels of positive psychotic symptoms, according to the study, and were more likely to have been rated as "improved" and as "not severely unwell." The CBD group also showed greater improvements in cognitive performance, but not by a wide enough margin to be statistically significant.

The study also noted that the CBD treatment was well-tolerated and adverse events were similar between the CBD group and the placebo group.

No comments:

Post a Comment